|
|
Mylan Inc.: PharmaVitae Profile |
| Published Date : 3 December 2010 |
|
|
|
Pages : 86 |
|
| |
|
|
|
|
|
|
|
Introduction
The analysis examines the historical and forecast performance for Mylan in the generic prescription pharmaceutical sector. The profile encompasses global company strategy and assessment of financial performance.
Features and benefits
* Gain insight in to Mylan's stategic outlook across the next 6 years.* Analyze company sales forecasts by therapy area, geography and formulation.
Highlights
Strategic insight into the prospects for Mylan over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales
Your key questions answered
* Benchmark Mylan's performance against key rivals in the generic prescription pharmaceutical sector.* See how the acquisition of Merck KGaA's generics unit continues to re-shape Mylan's business
|
|
|
|
Table of Contents : |
Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 200515
Financial performance, 200515
Mylan: PharmaVitae forecasts at a glance
Strategic insight
Impact of M&A over 2003-2015
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest quarterly sales
Latest prescription pharma product news
Q3 2010
Q2 2010
Q1 2010
Latest corporate news
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Q3 2009
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Early M&A boosts branded Prescription pharmaceuticals capacity
Matrix acquisition provides API capabilities
Acquisition of Merck Generics
Mylan potential for further M&A?
Current corporate structure
Generics Segment
Specialty Segment
Matrix Segment
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 200915
Branded and generic portfolio sales analysis
Therapy area analysis
Geographic analysis
Formulation analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 200309
Operating costs and profit analysis
Operating costs and profit analysis, 2003-09
OPERATING COST RATIO AND PROFIT MARGIN ANALYSIS, 2003-09
Operating cost ratio and profit margin analysis, 200915
Operating costs and profit analysis, 2009-15
KEY BRANDED PRODUCTS
Product portfolio
APPENDIX
Abbreviations |
|
|
|
Published By : Datamonitor |
|
|
Related
Keywords:
Energy,
Insurance, Financial,
Company Profile,
Industry Profile,
Swot Analysis,
Apparel,
Consumer, Trade,
Information technology,
Food,
Healthcare,
Construction,
Retail,
Design,Oil
and Gas,
Solar,
Miscellaneous,
Business,
Pharmaceuticals,
Technology,
Defense,
Medical,
Travel,
Power,
Metal
|
|
|
|
